Digest. Absorb. Nourish.
Patients living with serious medical conditions due to rare diseases often require enteral feeding for nutrition. Many of these patients struggle with digesting fat, essential for growth, immunity, and organ function. Unable to get the full nutritional benefits from enteral feeding, these patients may experience poor outcomes and significant health consequences as a result.
Alcresta develops rare disease, enzyme-based products helping to address fat malabsorption (often due to exocrine pancreatic insufficiency) in patients who are enterally fed at home or in the hospital. Our RELiZORB® cartridge contains iLipase®, a patented microbead/enzyme technology that breaks down fat for easy ingestion and optimal absorption.
The first and only enzyme product for use in enteral feeding. RELiZORB is a digestive enzyme cartridge designed to mimic the function of pancreatic lipase. RELiZORB helps children and adults on enteral tube feeding who have trouble breaking down and absorbing fats due to cystic fibrosis, short bowel syndrome, pancreatitis, digestive cancers, and other rare diseases.
RELiZORB clinical trials now enrolling patients
Short bowel syndrome (SBS)
- 90 day, Phase 3, open labeled exploratory study of RELiZORB. To learn more, visit ClinicalTrials.gov, trial NCT03530852
- 90 day observational study as an extension to the Phase 3, open labeled exploratory study of RELiZORB. To learn more, visit ClinicalTrials.gov, trial NCT05635747
Pancreatitis
- A Randomized Controlled Trial Evaluating the Efficacy of Immobilized Lipase (RELiZORB) During Enteral Nutrition in Patients with Exocrine Pancreatic Insufficiency Secondary to Acute Pancreatitis. To learn more, visit ClinicalTrials.gov, trial NCT06691893
- Open-label, Multicenter, Phase IV, Study Evaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis. To learn more, visit ClinicalTrials.gov, trial NCT07583342
Critical care
- A Double-Blind, Placebo-Controlled, Single-Center Proof of Concept Prospective Study Evaluating the Utility of RELiZORB for the Treatment of Feeding Intolerance in Critically Ill Adults with Multi-Organ Failure. To learn more, visit ClinicalTrials.gov, trial NCT05710315
RELiZORB Pediatric Gastrointestinal Patient Registry ENROLLMENT COMPLETE
Alcresta is conducting a pediatric direct-to-patient prospective observational data registry. Learn more.